GrafTech (EAF) Stock Jumps As Q3 Results Hint At Pricing Turnaround

GrafTech International climbed 14% to US$8.51 on Friday after its Q3 2026 report, a sharp move for a stock that had been under pressure over the past month. Traders are reacting to early signs that pricing power in graphite electrodes may be turning a corner, even as the income statement still shows a net loss of US$46.8 million on US$140.2 million of revenue. In the short term, the rally appears to be driven by relief. Over a longer horizon, the key question is whether this early pricing uptick can ease an intense profit squeeze that has defined GrafTech’s recent history.

Impressed by GrafTech International’s pricing hint but concerned that losses are still heavy at the bottom line? Check out our screener of list of solid balance sheet and fundamentals stocks (25 results) if you want ideas that combine pricing power with cleaner income statements.

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$140.2 million vs. US$144.0 million (top line slightly lower year on year)
• Net Loss (Q3 2026 vs Q3 2025): US$46.8 million loss vs. US$28.5 million loss (bottom line pressure increased, including restructuring charges)
• Basic EPS (Q3 2026 vs Q3 2025): US$1.76 loss per share vs. US$1.10 loss per share (per share result moved further into loss)
• Adjusted EBITDA (Q3 2026 vs Q3 2025): US$9 million vs. US$13 million (earnings before interest, tax, depreciation and amortization weakened)

GrafTech says 2027 electrode pricing steps up sharply from new contracts. Ask Charlie what turns GrafTech’s 2027 price jump into profits.

Evaluating GrafTech’s Margin-Recovery Milestones

The bullish pitch around GrafTech International hinges on turning better pricing and lower costs into real cash earnings, not just hope.

"The main thing that has to go right is that electrode pricing gains and cost reductions, supported by higher capacity utilization and energy hedging, translate into consistently positive EBITDA and operating cash flow after the recent period of weak profitability."

Q3 shows the first small pieces of that puzzle, not the full picture. Adjusted EBITDA of US$9 million and a much smaller operating cash outflow than Q2 point to early traction on cost work and capacity actions like the Monterrey closure. Realized prices stayed near US$3,900 per ton, so the core milestone of pricing led, self funding profitability is still ahead and tied to the higher 2027 contracts management describes.

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there.

GrafTech Bear Case: Cash Burn Eases, But Profitability Still Missing

Bearish investors argue GrafTech International is stuck in a low earnings, high cash usage loop that committed volumes alone cannot fix.

"Although GrafTech International has over 80% to 90% of expected 2026 volume already committed and is guiding to 5% to 10% volume growth, Q2 2026 adjusted EBITDA of only US$2 million and a reported adjusted free cash flow outflow of US$75 million show that higher contracted tonnage alone has not yet translated into healthier earnings or cash generation, which could limit the benefit of further volume-led revenue growth."

Q3 does not fully disprove that worry. Adjusted EBITDA improved to US$9 million and cash usage narrowed, yet the business still reported a US$47 million loss and negative adjusted free cash flow. Committed volume and early pricing traction are helping, but the milestone of self funding operations has not been reached, so the core bear argument around weak profitability largely survives this quarter.

Hunt Quiet Pricing Power Stories

GrafTech International just showed how a single quarter can sharpen questions about whether a turnaround truly has momentum. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 42% below our estimate - target large LED display upgrades for sports venues, transit hubs and youth facilities replacing outdated signage.
• Company 2 - 25% below our estimate - sell injectable therapies for weight management and diabetes as demand rises for obesity and metabolic treatments.
• Company 3 - 39% below our estimate - expand coconut based beverage ranges as retailers allocate shelf space from sugary drinks to hydration products.

That is three of the list. See the full list of 27 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com